Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Evoke Pharma (EVOK) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for Evoke Pharma (EVOK) over the last 6 years, with Q3 2025 value amounting to 26.56%.

  • Evoke Pharma's EBITDA Margin rose 218800.0% to 26.56% in Q3 2025 from the same period last year, while for Sep 2025 it was 35.99%, marking a year-over-year increase of 324600.0%. This contributed to the annual value of 50.77% for FY2024, which is 926600.0% up from last year.
  • Per Evoke Pharma's latest filing, its EBITDA Margin stood at 26.56% for Q3 2025, which was up 218800.0% from 41.55% recorded in Q2 2025.
  • In the past 5 years, Evoke Pharma's EBITDA Margin ranged from a high of 26.56% in Q3 2025 and a low of 2864.88% during Q1 2021
  • Over the past 5 years, Evoke Pharma's median EBITDA Margin value was 157.72% (recorded in 2023), while the average stood at 356.29%.
  • In the last 5 years, Evoke Pharma's EBITDA Margin crashed by 2000000000bps in 2021 and then soared by 23746100bps in 2022.
  • Evoke Pharma's EBITDA Margin (Quarter) stood at 429.14% in 2021, then soared by 50bps to 214.7% in 2022, then skyrocketed by 48bps to 112.64% in 2023, then soared by 68bps to 36.08% in 2024, then rose by 26bps to 26.56% in 2025.
  • Its EBITDA Margin was 26.56% in Q3 2025, compared to 41.55% in Q2 2025 and 42.26% in Q1 2025.